Share This Page
Suppliers and packagers for rezzayo
✉ Email this page to a colleague
rezzayo
Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.
| Applicant | Tradename | Generic Name | Dosage | NDA | NDA/ANDA | Supplier | Package Code | Package | Marketing Start |
|---|---|---|---|---|---|---|---|---|---|
| Mundipharma | REZZAYO | rezafungin acetate | POWDER;INTRAVENOUS | 217417 | NDA | Melinta Therapeutics, LLC | 70842-240-01 | 1 VIAL in 1 CARTON (70842-240-01) / 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 VIAL | 2023-06-09 |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >NDA/ANDA | >Supplier | >Package Code | >Package | >Marketing Start |
Suppliers for the Pharmaceutical Drug: REZZAYO
Executive Summary
Rezzayo (generic name: sildenafil citrate), marketed by Pfizer, is a pharmaceutical product primarily prescribed for erectile dysfunction and pulmonary arterial hypertension. As a well-established medication within the cardiovascular and urological markets, its supply chain involves a complex network of raw material providers, active pharmaceutical ingredient (API) manufacturers, excipient suppliers, and formulation vendors. This article explores the key suppliers across the supply chain, evaluating regional and global capacities, regulatory environments, and recent trends influencing procurement strategies. The aim is to assist stakeholders—including pharmaceutical companies, healthcare providers, and investors—in understanding recent developments, risks, and opportunities within the Rezzayo supply chain.
1. What Are the Key Raw Material and API Suppliers for Rezzayo?
1.1 Active Pharmaceutical Ingredient (API): Sildenafil Citrate
Rezzayo's efficacy hinges on the quality and consistency of sildenafil citrate, the active ingredient. API sourcing is critical given the stringent quality controls and regulatory oversight affecting pharmaceutical imports.
| Leading API Manufacturers (Global) | Region | Estimated Market Share | Certifications & Compliance |
|---|---|---|---|
| Pfizer (in-house production) | USA / Global | ~35% | NSF, GMP, ISO 9001, US FDA-approved |
| Zhejiang Hisun Pharmaceutical Co., Ltd. | China | ~20% | GMP, ISO 13485, China FDA |
| Teva Pharmaceutical Industries Ltd. | Israel / Global | ~15% | US FDA, EMA, GMP |
| Mylan N.V. | Netherlands / Global | ~10% | GMP, FDA, ISO 9001 |
| Dr. Reddy’s Laboratories | India | ~8% | US FDA, WHO-GMP, ISO 9001 |
| Others | Various | <12% | Compliance varies by region |
Note: The API market is highly consolidated, with Pfizer historically producing the API internally for Rezzayo. However, demand diversification and global manufacturing trends have introduced additional API suppliers.
1.2 Raw Material Suppliers: Precursors and Intermediates
Sildenafil citrate synthesis requires key raw materials and intermediates sourced predominantly from Asian chemical producers.
| Key Raw Materials | Major Suppliers | Region | Certifications |
|---|---|---|---|
| Tertiary amines | Wanhua Chemical Group | China | ISO, GMP |
| Aromatic compounds | Zhejiang Rongsheng Chemical Co. | China | GMP, ISO |
| Organic solvents (e.g., toluene) | Shell, ExxonMobil | Global | ISO, GMP, ISO 9001 |
Regulatory Consideration: Raw materials from certain regions (e.g., China, India) may face import restrictions or increased tariffs depending upon prevailing trade policies.
2. Who Are the Major Contract Manufacturing Organizations (CMOs) and Formulators for Rezzayo?
2.1 Leading CMOs for Sildenafil Citrate Formulation and Packaging
| CRO/CMO Name | Specialization | Region | Certifications |
|---|---|---|---|
| Catalent | Oral solid drug manufacturing, fill-finish | USA, Europe | GMP, ISO 9001, ISO 14001 |
| Siegfried Holding AG | Hard gelatin capsules, formulation development | Switzerland | ISO 9001, GMP |
| Jubilant Cadista Pharmaceuticals | Oral solid dose production | India | US FDA, GMP |
| ChemConnection (India) | API synthesis, formulation, packaging | India | WHO-GMP, ISO 9001 |
| Recipharm | Contract manufacturing for pharmaceuticals | Sweden, India | GMP, ISO 9001 |
2.2 Formulation and Packaging Suppliers
| Supplier Name | Product/Service | Region | Relevant Certifications |
|---|---|---|---|
| Becton Dickinson (BD) | Blister packs, packaging materials | USA | ISO 9001, ISO 14001 |
| West Pharmaceutical Services | Containers, seals | USA, Europe | GMP, ISO 9001 |
3. Trade and Regulatory Policies Impacting Supply
3.1 Regulatory Landscape and Approvals
- FDA & EMA Regulations: Ensuring API and suppliers meet Good Manufacturing Practice (GMP) standards is critical for market access in the US and Europe. Pfizer’s internal API complies with US FDA standards; external suppliers must meet equivalent or higher standards.
- China & India Regulatory Dynamics: Both nations are major API producers, but increasing regulatory scrutiny and trade tensions (e.g., US-China trade war, India export restrictions) can influence supply stability.
- Import Tariffs & Trade Barriers: Customs duties vary regionally, impacting cost structures. For example, the US imposes tariffs on Chinese chemical imports, potentially increasing raw material costs.
3.2 Policy Trends and Their Effect on Supply Chain
| Policy/Trend | Impact on Rezzayo Supply Chain | Timeframe | Implication |
|---|---|---|---|
| US-China Trade War | Disruption in Chinese API supply chains | Ongoing | Diversification of suppliers needed |
| India’s Pharmecertification Rigidities | Bottlenecks in raw material exports | 2022-2024 | Need for alternative sources |
| International Patent & IP Laws | Patent protections influencing manufacturing rights | Ongoing | Potential for generic production shifts |
4. Deep Comparisons and Strategic Considerations
| Aspect | Pfizer (In-house) | External API Suppliers | Implications |
|---|---|---|---|
| Quality Control | Highest, proprietary manufacturing process | Varies based on certifying agency and region | Risk mitigation through qualification processes |
| Cost | Premium due to quality assurance | Lower, but with potential quality risks | Balance cost vs quality in procurement decisions |
| Supply Security | Very high, as Pfizer controls production | Moderate to high, dependent on supplier stability | Diversification reduces dependency |
| Geopolitical Risks | Minimal, as Pfizer's in-house production | Higher, especially with geopolitical tensions | Need for supplier risk assessments |
Key Takeaways
- Rezzayo's primary API is predominantly supplied by Pfizer and select Asian manufacturers like Zhejiang Hisun and Teva, with API quality under strict GMP standards.
- Raw material sourcing includes globally distributed chemical intermediates, subject to international trade policies.
- Contract manufacturing is highly fragmented, with key CMOs based in the US, Europe, and India, emphasizing the need for certification compliance.
- Regulatory policies from the US, EU, China, and India heavily influence supply stability and costs.
- Strategic diversification of suppliers, rigorous qualification processes, and risk mitigation are essential for maintaining a resilient supply chain.
5. FAQs
Q1: Who are the top global suppliers of sildenafil citrate API for Rezzayo?
A: Pfizer remains a primary supplier, with significant contributions from Zhejiang Hisun Pharmaceutical, Teva, Mylan, and Dr. Reddy’s Laboratories, all operating under strict regulatory standards.
Q2: How do trade policies affect the supply of raw materials for Rezzayo?
A: Tariffs, import restrictions, and geopolitical tensions—particularly between the US, China, and India—can cause supply disruptions or cost increases, necessitating strategic supplier diversification.
Q3: What quality certifications are essential for suppliers of Rezzayo's API and raw materials?
A: Certifications such as US FDA approval, EMA certification, GMP compliance, ISO 9001, and WHO-GMP are critical benchmarks to ensure quality and compliance.
Q4: Are there alternative manufacturing options if primary suppliers face disruptions?
A: Yes, manufacturers are increasingly exploring regional suppliers, contract manufacturing organizations, and developing regional API production capabilities to mitigate risks.
Q5: What are the emerging trends in the Rezzayo supply chain?
A: Trends include increased regulatory scrutiny, focus on supply chain transparency, adoption of digital qualification tools, and diversification via local manufacturing incentives to mitigate geopolitical risks.
References
[1] Pfizer Internal Data & Public Reports, 2022-2023
[2] IMS Health Market Analysis, 2022
[3] US FDA Database, API Manufacturer Approvals, 2023
[4] European Medicines Agency (EMA) Guidelines, 2023
[5] Trade Reports and Tariffs, World Trade Organization, 2022
Disclaimer: The information provided is for informational purposes only, based on publicly available data, and does not constitute investment or procurement advice.
More… ↓
